Paralel Advisors LLC Takes Position in Cardinal Health, Inc. $CAH

Paralel Advisors LLC acquired a new position in Cardinal Health, Inc. (NYSE:CAH) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,932 shares of the company’s stock, valued at approximately $2,597,000.

Other institutional investors have also recently made changes to their positions in the company. Integrated Wealth Concepts LLC grew its position in Cardinal Health by 6.9% during the 1st quarter. Integrated Wealth Concepts LLC now owns 4,363 shares of the company’s stock worth $601,000 after purchasing an additional 280 shares during the period. Jones Financial Companies Lllp boosted its stake in shares of Cardinal Health by 198.3% in the first quarter. Jones Financial Companies Lllp now owns 21,112 shares of the company’s stock worth $27,000 after buying an additional 14,034 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in Cardinal Health during the second quarter worth about $1,935,000. Cerity Partners LLC grew its holdings in Cardinal Health by 17.0% during the second quarter. Cerity Partners LLC now owns 40,426 shares of the company’s stock worth $6,792,000 after acquiring an additional 5,880 shares during the period. Finally, Nebula Research & Development LLC raised its position in Cardinal Health by 34.4% during the second quarter. Nebula Research & Development LLC now owns 10,334 shares of the company’s stock valued at $1,736,000 after acquiring an additional 2,646 shares in the last quarter. Hedge funds and other institutional investors own 87.17% of the company’s stock.

Cardinal Health Trading Down 2.5%

NYSE CAH opened at $228.95 on Friday. The stock has a market capitalization of $53.25 billion, a price-to-earnings ratio of 31.67, a PEG ratio of 1.26 and a beta of 0.49. Cardinal Health, Inc. has a twelve month low of $145.87 and a twelve month high of $258.30. The stock has a 50-day moving average of $231.91 and a 200 day moving average of $217.78.

Cardinal Health (NYSE:CAH) last issued its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.42 by $0.49. The company had revenue of $63.67 billion for the quarter, compared to analyst estimates of $65.15 billion. Cardinal Health had a negative return on equity of 98.53% and a net margin of 0.67%.Cardinal Health’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company earned $2.08 earnings per share. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. Equities analysts predict that Cardinal Health, Inc. will post 12.54 EPS for the current fiscal year.

Cardinal Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Thursday, October 1st will be issued a $0.5158 dividend. This represents a $2.06 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, October 1st. Cardinal Health’s payout ratio is presently 28.49%.

Insider Buying and Selling

In other Cardinal Health news, insider Michelle D. Greene sold 11,650 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $235.72, for a total transaction of $2,746,138.00. Following the completion of the transaction, the insider directly owned 10,330 shares in the company, valued at approximately $2,434,987.60. This represents a 53.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jason M. Hollar sold 44,529 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $236.18, for a total transaction of $10,516,859.22. Following the transaction, the chief executive officer directly owned 190,603 shares in the company, valued at approximately $45,016,616.54. The trade was a 18.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 210,271 shares of company stock worth $49,626,657 in the last 90 days. 0.12% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on CAH shares. JPMorgan Chase & Co. boosted their price target on Cardinal Health from $215.00 to $260.00 and gave the company a “neutral” rating in a report on Thursday, August 13th. Barclays raised their price objective on shares of Cardinal Health from $258.00 to $275.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Evercore reaffirmed an “outperform” rating and set a $270.00 target price on shares of Cardinal Health in a report on Wednesday, August 12th. Wall Street Zen upgraded shares of Cardinal Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 4th. Finally, Mizuho increased their price target on shares of Cardinal Health from $240.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $266.56.

Trending Headlines about Cardinal Health

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Royal Bank of Canada initiated coverage of Cardinal Health with a “moderate buy” or outperform-equivalent rating. RBC cited the integration of higher-margin services as a potential driver of future earnings outperformance. RBC Capital Starts Cardinal Health at Outperform
• Positive Sentiment: A Zacks analysis identified CAH as a potentially attractive long-term value stock, while recent coverage has highlighted Cardinal Health’s precision-medicine operations and higher-margin services as sources of sustained growth. Why Cardinal Health Is a Top Value Stock for the Long-Term
• Neutral Sentiment: Brokerages continue to assign Cardinal Health a consensus “moderate buy” rating. The constructive view is tempered by valuation and questions about the sustainability of recent earnings gains.
• Negative Sentiment: Multiple executives and insiders sold shares around $235–$237. Chief Executive Officer Jason Hollar sold a combined 124,529 shares worth approximately $29.4 million, while CEO Deborah Weitzman sold about $1.7 million. Other insider sales included Chief Accounting Officer Mary Scherer and executives Michelle Greene, Jessica Mayer, and Stephen Mason. The transactions substantially reduced several executives’ holdings and may signal that insiders are taking profits after the stock’s strong rally. Cardinal Health Insider Sale Filing
• Negative Sentiment: Although Cardinal Health reported adjusted quarterly EPS of $2.91, well above the $2.42 consensus, an analysis noted that a significant portion of the earnings improvement came from a one-time tariff refund. That raises concerns about the durability of the earnings beat and may be contributing to the weaker stock performance. Cardinal Health Earnings Analysis

Cardinal Health Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.